{"id":"NCT02409342","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","officialTitle":"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-20","primaryCompletion":"2020-02-04","completion":"2022-03-08","firstPosted":"2015-04-06","resultsPosted":"2021-02-18","lastUpdate":"2023-03-15"},"enrollment":572,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody","otherNames":["MPDL3280A, RO5541267"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]}],"arms":[{"label":"(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","type":"ACTIVE_COMPARATOR"},{"label":"Atezolizumab","type":"EXPERIMENTAL"}],"summary":"This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.","primaryOutcome":{"measure":"Overall Survival (OS) in the TC3 or IC3-WT Populations","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)","effectByArm":[{"arm":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","deltaMin":13.1,"sd":null},{"arm":"Atezolizumab","deltaMin":20.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0106"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":142,"countries":["United States","Brazil","China","France","Germany","Greece","Hungary","Italy","Japan","Poland","Romania","Russia","Serbia","South Korea","Spain","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["39532375","32997907"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":263},"commonTop":["Anaemia","Nausea","Constipation","Decreased appetite","Fatigue"]}}